Drug intelligence / Profile preview

KB39

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

KB39 is an investigational **synthetic glycan** designed to modulate the **gut microbiome** and increase production of **propionate**, a short-chain fatty acid associated with favorable metabolic effects. The compound was identified through ex vivo screening of a large synthetic glycan library for high propionate-producing capacity. In preclinical studies, KB39 enriched propionate-producing gut bacteria and increased propionate biosynthetic genes, leading to reductions in serum total cholesterol, LDL-cholesterol, insulin, hepatic triglycerides, hepatic cholesterol, atherosclerosis, liver steatosis, and inflammatory measures in western diet-fed LDL receptor knockout mice. It is being explored as a microbiome-directed therapeutic for cardiometabolic disease states such as metabolic syndrome, insulin resistance, dyslipidemia, obesity, and related atherosclerotic and fatty liver phenotypes.

Targets

BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on KB39.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB39.

Explore the full profile